{
  "asset": "RYBREVANT (amivantamab)",
  "query_terms": [
    "RYBREVANT (amivantamab)",
    "amivantamab",
    "RYBREVANT"
  ],
  "returned_unique": 21,
  "kept": 10,
  "studies": [
    {
      "nct_id": "NCT05379595",
      "title": "A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Advanced or Metastatic Colorectal Cancer"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab IV",
        "Fluorouracil",
        "Leucovorin",
        "Oxaliplatin",
        "Irinotecan",
        "Amivantamab"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT05379595"
    },
    {
      "nct_id": "NCT07276399",
      "title": "A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants With Treatment-Na√Øve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma",
      "overall_status": "RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Squamous Cell Carcinoma of Head and Neck"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Pembrolizumab",
        "Carboplatin",
        "5-Flurouracil",
        "Cisplatin"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07276399"
    },
    {
      "nct_id": "NCT07227025",
      "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic Non-small Cell Lung Cancer",
      "overall_status": "RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Olomorasib"
      ],
      "last_update": "2025-12-19",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT07227025"
    },
    {
      "nct_id": "NCT04988295",
      "title": "A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Lazertinib",
        "Amivantamab",
        "Pemetrexed",
        "Carboplatin"
      ],
      "last_update": "2025-12-23",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04988295"
    },
    {
      "nct_id": "NCT04606381",
      "title": "An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Amivantamab, a Human Bispecific EGFR and cMet Antibody for the Treatment of Advanced Solid Malignancies",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Advanced Solid Malignancies"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Ami-LC-MD",
        "Ami-LC",
        "Ami-HC",
        "Ami-HC-CF",
        "Lazertinib"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04606381"
    },
    {
      "nct_id": "NCT04538664",
      "title": "A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Pemetrexed",
        "Carboplatin",
        "Pemetrexed"
      ],
      "last_update": "2025-12-23",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04538664"
    },
    {
      "nct_id": "NCT04077463",
      "title": "An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Lazertinib",
        "Amivantamab",
        "Carboplatin",
        "Pemetrexed"
      ],
      "last_update": "2025-12-24",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04077463"
    },
    {
      "nct_id": "NCT06532032",
      "title": "A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Docetaxel Combination Therapy in Metastatic Non-small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 2",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Docetaxel"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT06532032"
    },
    {
      "nct_id": "NCT02609776",
      "title": "A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects With Advanced Non-Small Cell Lung Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 1",
      "conditions": [
        "Non-Small-Cell Lung Cancer"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Amivantamab",
        "Lazertinib",
        "Carboplatin",
        "Pemetrexed"
      ],
      "last_update": "2025-12-05",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT02609776"
    },
    {
      "nct_id": "NCT04487080",
      "title": "A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer.",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "phase": "Phase 3",
      "conditions": [
        "Carcinoma, Non-Small-Cell Lung"
      ],
      "lead_sponsor": "Janssen Research & Development, LLC",
      "collaborators": [],
      "interventions": [
        "Amivantamab",
        "Osimertinib",
        "Lazertinib",
        "Placebo"
      ],
      "last_update": "2025-12-23",
      "ctgov_url": "https://clinicaltrials.gov/study/NCT04487080"
    }
  ]
}